Abstract:

Sodiumglucose cotransporter 2 inhibitors (SGLT2i), the most recently developed oral hypoglycemic agents acted on renal proximal tubules, suppress glucose reabsorption and increase urinary glucose excretion. Besides their ability to lower plasma glucose, blood pressure, plasma uric acid concentration and the cardiovascular (CV) safety by decreasing the independent CV risk factors, the SGLT2i offers the possibility of kidney protection. Simultaneous use of SGLT2i and RAAS blockers are novel strategies to slow the progression of diabetic kidney disease (DKD). The present review was to review the mechanisms of potentially renoprotective benefits of SGLT2i in patients with DKD.

Key words: sodium-glucose co-transporter 2 inhibitors, diabetic kidney disease